Center for Medical Technology Policy

What Center for Medical Technology Policy does

Center for Medical Technology Policy (CMTP) is an independent 501(c)(3) non-profit research organization headquartered at the World Trade Center in Baltimore, Maryland. Founded by Sean Tunis, MD, MSc — a former CMS Chief Medical Officer who oversaw clinical policy for Medicare and Medicaid programs covering over 100 million US citizens — CMTP works to improve healthcare by enhancing the quality, relevance, and efficiency of clinical research. The organization develops comparative effectiveness research (CER) and patient-centered outcomes research (PCOR) methodologies, producing condition-specific Effectiveness Guidance Documents (EGDs) that provide methodological standards for designing clinical studies intended to inform decisions by patients, clinicians, and payers. Its product portfolio includes EGDs spanning Alzheimer's, chronic wounds, atrial fibrillation, oncology molecular diagnostics, diabetes, hemophilia, asthma, sickle cell disease, NASH, and Duchenne Muscular Dystrophy, as well as Core Outcome Sets developed through multi-stakeholder consensus processes and guidance on pragmatic clinical trials.

The organization's flagship convening platform is the Green Park Collaborative (GPC), a multi-stakeholder forum where payers, life sciences companies, patient groups, clinicians, researchers, and regulators engage in dialogue regarding methodological standards for evidence generation. GPC operates alongside GPC-International in partnership with Health Technology Assessment International (HTAi). CMTP's business model is grant-funded and membership-driven: primary revenue comes from grants from foundations and government agencies (PCORI, NIH, Edwards Lifesciences Foundation, BioMaryland Center) and recurring membership and partnership fees from life sciences industry sponsors participating in initiatives such as coreHEM (hemophilia gene therapy, sponsored by Bayer, BioMarin, Pfizer, Shire, Spark Therapeutics, uniQure, and St. Jude). The organization does not sell commercial products but distributes guidance documents, white papers, and publications through its website and stakeholder networks. Key collaborators include Harvard Pilgrim Health Care Institute (National Patient-Centered Research Network), Fred Hutchinson Cancer Research Center (cancer research prioritization), the National Hemophilia Foundation and McMaster University (coreHEM), Quintiles (uterine fibroids CER), the University of California's ATHENA Breast Health Network, and Avalere Health.

Name

Center for Medical Technology Policy

Legal name

Center for Medical Technology Policy

Website

https://cmtpnet.org

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Center for Medical Technology Policy is a Baltimore-based 501(c)(3) non-profit that develops comparative effectiveness research methodologies and multi-stakeholder consensus guidance — including Effectiveness Guidance Documents, Core Outcome Sets, and the Green Park Collaborative forum — to inform clinical and payer decision-making for life sciences companies, payers, regulators, and patient groups.

Ownership category

akta.pro rank

Product category

Comparative Effectiveness Research Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Investigator & Site Training / GCP Support (HLAGACAF)

Keywords

• Comparative effectiveness research
• Patient-centered outcomes research
• Effectiveness guidance documents
• Core outcome sets
• Stakeholder engagement services

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Grant Funding: CMTP operates as a 501(c)(3) non-profit organization that receives grants from foundations and government agencies including PCORI, NIH, and Edwards Lifesciences Foundation to fund its research initiatives.
2. Membership and Partnership Fees: Green Park Collaborative-USA operates as a membership-based forum where payers, life sciences companies, patient groups, clinicians, researchers, and regulators engage in dialogue regarding methodological standards.

Distribution channels4 records

Marketing channels7 records

Core offering

CMTP develops and disseminates Effectiveness Guidance Documents (EGDs) — condition-specific methodological recommendations for clinical study design — and operates the Green Park Collaborative (GPC), a multi-stakeholder forum where patients, clinicians, payers, regulators, life sciences companies, and researchers reach consensus on evidence standards. It also develops standardized Core Outcome Sets for clinical trials in therapeutic areas including hemophilia, asthma, sickle cell disease, and NASH, and provides Stakeholder Engagement Services to integrate patient and payer perspectives throughout the clinical research process.

Product overview

Center for Medical Technology Policy (CMTP) is an independent non-profit 501(c)(3) organization that improves healthcare effectiveness by enhancing clinical research quality and relevance. The organization operates as a research and policy institute rather than a traditional product company, offering Effectiveness Guidance Documents (EGDs) as its primary methodological framework, supplemented by the Green Park Collaborative multi-stakeholder forum for evidence development. CMTP also develops Core Outcome Sets through consensus processes for various disease areas, provides stakeholder engagement services for research projects, and offers guidance on pragmatic clinical trials. These offerings work together to help patients, clinicians, and payers make informed treatment and policy decisions through better evidence.

Differentiator

Problem solved

Functional benefit

Products and services

• Effectiveness Guidance Documents (EGDs) Condition-specific methodological recommendations for designing comparative effectiveness studies, intended to inform clinical and payment decisions. EGDs are developed through multi-stakeholder consensus and serve researchers and life sciences companies needing clarity on evidence standards.
• Green Park Collaborative (GPC) A multi-stakeholder membership forum where payers, life sciences companies, patient groups, clinicians, researchers, and regulators engage in dialogue and reach consensus on methodological standards for clinical studies and evidence generation that informs coverage and payment decisions in the United States.
• Core Outcome Sets Standardized minimum sets of outcomes developed through multi-stakeholder consensus processes for specific clinical conditions including hemophilia (coreHEM), asthma (coreASTHMA), sickle cell disease (coreSCD), and NASH (coreNASH). These allow fair comparisons between alternative treatments and ensure patient perspectives are included in clinical trials.
• Stakeholder Engagement Services Facilitation services that elicit input from patients, clinicians, payers, regulators, life sciences companies, researchers, and policymakers throughout the clinical research process, used by academic consortia, research networks, and government-funded studies.
• Pragmatic Clinical Trials Guidance Methodological guidance for designing practical clinical trials that evaluate treatments in real-world settings, supporting researchers and life sciences companies that need pragmatic trial evidence for coverage and payment decisions.

Quantifiable outcome

• coreHEM developed first set of guidelines for minimum outcomes in hemophilia gene therapy clinical trials, ensuring patient perspectives and fair comparisons
• +2 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, minor and major.

• National Hemophilia FoundationcoreStrategic or Co-development Partner · 21 May 2018Joint leadership of coreHEM initiative, a multi-stakeholder partnership to develop core outcome sets for hemophilia gene therapy clinical trials. The partnership ensures patient perspectives on critical outcomes are included in pivotal trials, allowing fair comparisons between alternative treatments.
• McMaster UniversitycoreStrategic or Co-development Partner · 21 May 2018Joint leadership of coreHEM initiative, providing academic expertise in evidence-based medicine and health research methodology. McMaster leads the consensus process for core outcome set development.
• BioMaryland CenterminorStrategic or Co-development Partner · 12 August 2014$1M partnership to incorporate health care quality and cost reduction criteria in biotechnology awards program, with preference for projects improving patient outcomes and reducing costs.
• Harvard Pilgrim Health Care InstitutecoreStrategic or Co-development Partner · 18 September 2013CMTP part of $9 million contract for National Patient-Centered Research Network. CMTP heads the Patient and Consumer Engagement in Research Subcommittee within the coordinating center managing a nationwide data network for CER.
• Fred Hutchinson Cancer Research CentercoreStrategic or Co-development Partner · 18 September 2013$1 million grant collaboration on structured cancer research prioritization using stakeholder input and Value of Information analysis. CMTP responsible for stakeholder recruitment and training.
• QuintilescoreStrategic or Co-development Partner · 4 June 2013CMTP supported PCORI-funded comparative effectiveness research comparing treatments for uterine fibroids. Penny Mohr, CMTP VP of Program Development, provided support for analysis of 33,000+ patient records.
• ATHENA Breast Health Network (University of California)coreStrategic or Co-development PartnerPartnership to revolutionize breast cancer care and molecular diagnostics by merging research, technology, financing and healthcare delivery. CMTP led the Biomarker Stakeholder Advisory Group and developed business plan for sustainable partnerships.
• Avalere HealthmajorStrategic or Co-development PartnerCollaboration with Avalere Health to support establishment and launch of Partnership for Enhanced Recovery focused on surgical patient outcomes improvement.
• Maryland Department of Health and Mental Hygiene (DHMH)minorStrategic or Co-development PartnerJoint partnership with BioMaryland Center offering $1M in awards for projects improving patient outcomes and reducing healthcare costs.
• Health Technology Assessment International (HTAi)majorStrategic or Co-development PartnerPartnership with HTAi to manage GPC-International, assessing feasibility of developing global guidance for the life sciences industry on clinical study design meeting HTA and coverage body needs.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AcademyHealth: Non-profit professional society dedicated to advancing health services research and CER. Comparable as a convening body for health services researchers and policy stakeholders.
• Institute for Clinical and Economic Review (ICER): Independent non-profit that produces comparative effectiveness reports and value-based price benchmarks to inform payer coverage decisions. Directly comparable to CMTP in its mission to bridge clinical evidence and reimbursement/payer decisions.
• National Quality Forum (NQF): Non-profit that builds consensus on healthcare performance measurement and quality standards. Comparable in role as a multi-stakeholder consensus convener for healthcare evidence and standards.
• National Pharmaceutical Council (NPC): Non-profit that funds and disseminates comparative effectiveness research and real-world evidence to inform health policy. Directly comparable as a CER-focused organization working with life sciences sponsors and payers.
• ECRI (formerly ECRI Institute): Independent non-profit that conducts evidence-based research, technology assessments, and patient safety analysis for healthcare providers and payers. Comparable as a non-profit evidence-generating body serving healthcare decision-makers.
• Patient-Centered Outcomes Research Institute (PCORI): Government-funded non-profit that funds patient-centered comparative clinical effectiveness research. Directly comparable as a key CER/PCOR funder and stakeholder CMTP serves and partners with.

Broad incumbents

• Avalere Health: Healthcare consulting firm that advises life sciences companies on evidence, policy, and reimbursement strategy. Comparable in working with pharma on coverage and evidence strategy; broader commercial consulting scope than CMTP.
• National Academy of Medicine (NAM): Independent advisor to the nation on health and biomedical science, producing consensus reports on clinical effectiveness and health policy. Comparable as a non-partisan convening body producing authoritative clinical evidence guidance.
• RTI International: Large non-profit research institute with significant health services and comparative effectiveness research practice. Comparable in conducting CER/PCOR research for government and life sciences clients, but broader scientific scope.

Emerging players

• Health Technology Assessment International (HTAi): International society focused on health technology assessment, with which CMTP partners on GPC-International. Comparable in producing HTA-related methodological standards; serves as a global counterpart and partner rather than direct US competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• Xx.com/cmtp_baltimore
• Facebookfacebook.com/cmtp.baltimore
• LinkedInlinkedin.com/company/center-for-medical-technology-policy

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Center for Medical Technology Policy